Skeletal Muscle Parameters of Liver Cirrhosis in Non-invasive Imaging and Outcome
ConditionLiver Cirrhosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorUniversity Hospital, Bonn
About this trial
The principal aim of this study is to analyse L3-SMI (skeletal muscle index) in a cohort of patients with decompensated liver cirrhosis and TIPS (transjugular intrahepatic portosystemic shunt), and compare the prognostic power with TPMT (transverse psoas muscle thickness). Furthermore, the role of myosteatosis, determined in CT by L3-SMI, MRI and ultrasound will be studied.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
liver cirrhosis of any etiology
CT scan available
Disqualifiers
HCC or any malignant disease
Trial population
Patients with liver cirrhosis of any etiology and CT scan available
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
imaging
Diagnostic testcomputed tomography, magnetic resosnance imaging, ultrasound
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Survival time
time of survival
Time frame
up to 60 monthsSecondary outcomes
1
Time to clinical acute decompensations
time to occurrence of acute decompensations of liver cirrhosis (readmissions, hepatic encephalopathy, bleeding, ascites, hepatorenal syndrome, infections)
Time frame
up to 60 months2
Time to clinical acute-on-chronic liver failure
acute-on-chronic liver failure according to EASL-CLIF-C definition (grade 1 (best) to 3 (worst)
Time frame
up to 60 months3
Development of sarcopenia
Assessment of sarcopenia according to EASL-guideline
Time frame
up to 60 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital, Bonn
Lead sponsor
University of Roma La Sapienza
Collaborator
Source ClinicalTrials.gov